You may have seen recent headlines that Hims & Hers pulled a planned launch of a compounded “Wegovy-like” product after pressure from the U.S. Food and Drug Administration.
That alone should get the attention of any practice offering GLP-1s.
But there’s a second, less discussed issue that matters just as much: Hims & Hers is also facing scrutiny tied to a U.S. Department of Justice investigation related to compounded semaglutide and marketing practices. And while federal investigations do not always end in convictions, they are often business-ending even when they resolve through settlements or are ultimately dropped. The cost, distraction, reputational damage, and operational strain can be devastating.
For brick-and-mortar medical practices and telemedicine providers, this moment is not about panic.
It is about clarity.
The February 6 FDA Warning Matters More Than It May Seem
On February 6, the FDA issued a public communication addressing non-FDA-approved GLP-1 products, with a particular focus on compounded versions and how they are promoted and used.
While the FDA did not ban compounded GLP-1s, the message was clear:
the agency is increasingly concerned with how these drugs are being marketed, labeled, and positioned to patients, especially where claims blur the line between compounded products and FDA-approved medications.
In regulatory terms, this type of guidance often functions as a line in the sand. Once issued, it becomes far easier for regulators to argue that practices “should have known” what was expected.
For medical practices, the February 6 warning reinforces a broader trend:
- Compounding is permitted only within narrow clinical and regulatory boundaries
- Marketing language matters as much as sourcing
- “Workarounds” and consumer-style messaging are increasingly risky
This context makes the recent Hims & Hers developments less surprising—and more instructive for the rest of the industry.
Why This Matters Beyond Big Telehealth
It’s easy to assume that enforcement actions against large, national platforms won’t affect smaller practices. In reality, large telehealth cases often set the tone for what regulators expect from everyone else next.
Historically, enforcement follows a familiar pattern:
- High-visibility platform
- Public regulatory messaging
- State-level investigations
- Downstream scrutiny of smaller operators using similar models
What happens to the biggest players today often becomes the compliance baseline for independent practices tomorrow.
Key Takeaways for Practices Offering GLP-1s
1. Compounded semaglutide is a narrow legal pathway, not a workaround
Compounding exists for specific, limited purposes, primarily related to shortages and clinical necessity. It is not a substitute business model for brand-name drugs, and regulators are increasingly focused on practices that treat it as such.
If your model relies on compounding to broadly replace FDA-approved products, that is a red flag.
2. FDA enforcement is focusing on marketing as much as sourcing
Many practices focus heavily on where they buy compounded GLP-1s. That matters. But enforcement is increasingly about how these products are described, advertised, and positioned to patients.
High-risk marketing includes:
- “Wegovy-like” or “Ozempic equivalent” language
- Claims of sameness or superiority
- Weight-loss guarantees or lifestyle marketing disconnected from medical necessity
- Minimizing or glossing over risks
Even properly sourced products can create exposure if marketing language is non-compliant.
3. Telehealth enforcement sets expectations for in-person clinics
Regulators do not view compliance differently just because a practice is smaller or brick-and-mortar. If anything, telehealth enforcement clarifies what regulators believe “good behavior” should look like across the board.
Practices should assume:
- Increased scrutiny of prescribing practices
- Greater attention to documentation and consent
- Closer review of advertising and patient communications
What Practices Should Be Reviewing Right Now
This is a good moment for practices to take a calm, proactive look at their GLP-1 programs:
- Sourcing: Are products coming from appropriate 503A pharmacies, and is that documented?
- Medical necessity: Are prescribing decisions individualized and defensible?
- Documentation: Does the chart clearly support the prescription?
- Consent forms: Do they accurately describe compounded medications, risks, and alternatives?
- Marketing language: Would a regulator reading your website or ads understand that this is a medical treatment, not a consumer product?
Most practices are not trying to cut corners. They are trying to meet patient demand while navigating shortages, pricing pressure, and genuinely confusing guidance. But intent does not insulate a practice from enforcement.
The Bottom Line
The lesson from the Hims & Hers situation is simple:
If you are offering GLP-1s, your sourcing, documentation, consent forms, and marketing language all need to line up.
Compliance does not have to slow growth.
But ignoring it eventually will.
If you are unsure whether your GLP-1 program is aligned with current enforcement trends, now is the right time to review it—before regulators do.